TORONTO - MediPharm Labs Corp., a pharmaceutical company specialized in precision-based cannabinoids announced its financial results for the three months ended March 31, 2024. Select Highlights Revenue increased 67% to $9.8M during the three months ended March 31, 2024 ("Q1 2024") versus revenue for the same quarter in 2023 ("Q1 2023") of $5.8M. Q1 2024 gross profit was $2.7M or 27% which improved significantly...

EDMONTON, AB - Aurora Cannabis Inc., a leading global medical cannabis company, appointed Rajesh Uttamchandani to the Company's Board of Directors. Mr. Uttamchandani joins the Board with notable expertise in strategy development, innovation, human capital and governance. His impressive career is characterized by executive level roles with leading businesses in emerging technology, FinTech, human capital consulting and global education. Most recently, he was...

COSTA MESA, Calif. - Gold Flora Corporation, a leading vertically-integrated California cannabis company, announced its financial results for the three-month period ("Q1 2024"). All amounts are expressed in U.S. dollars. Q1 2024  Financial Highlights Total revenue was $32.2 million, representing a 13% sequential growth; Q1 2024 gross profit was $10.0 Million, representing a 31% gross margin; Q1 2024 adjusted gross profit1 of $17.4 million, representing a 54%...

DENVER - Medicine Man Technologies Inc., operating as Schwazze, announced financial and operational results for the first quarter ended March 31, 2024. "We delivered another period of revenue growth in Q1 as we further refined our retail strategy while contending with the prolonged competitive challenges in Colorado and New Mexico," said Forrest Hoffmaster, Interim CEO of Schwazze. "Throughout the quarter, we continued...

TORONTO -- TerrAscend Corp., a leading North American cannabis company, today reported its financial results for the first quarter ended March 31, 2024. All amounts are expressed in U.S. dollars and are prepared under U.S. Generally Accepted Accounting Principles (GAAP), unless indicated otherwise. The following financial measures are reported as results from continuing operations due to the shutdown of the...

NEW YORK -- Curaleaf Holdings, Inc., a leading international provider of consumer products in cannabis, reported its financial and operating results for the first quarter ended March 31, 2024. All financial information is reported in accordance with U.S. generally accepted accounting principles (GAAP) and is provided in U.S. dollars unless otherwise indicated. Boris Jordan, Executive Chairman of Curaleaf, stated, "Consistent with our...

HERZLIYA, Israel, and ALGARY, AB -- Innocan Pharma Corporation, a pioneer in the pharmaceutical and biotechnology industries, conducted a  successful pre-clinical treatment with a liposomal-CBD injection in a female donkey. Innocan's innovative therapy provided immediate noticeable pain relief and improved mobility. Miri, a 7-year-old female donkey, underwent amputation of her right front limb at a young age, resulting in a weight...

TORONTO - Auxly Cannabis Group Inc., a leading consumer packaged goods company in the cannabis products market, today released its financial results for the three months ended March 31, 2024.  These filings and additional information regarding Auxly are available for review on SEDAR at www.sedar.com. Q1 2024 Highlights and Subsequent Events Auxly achieved its best Q1 in its history across key metrics of revenue, margin and...

LONDON - The UK is the primary driver of new growth in Europe’s medical cannabis market, with sales of medical cannabis greater than expected due to ‘unusually high’ consumption volumes on a per-patient basis. By the end of 2024, for example, 62,960 patients are forecasted to be using medical cannabis in the UK, generating €240 million (£205 million) in sales,...

TORONTO and GLIL YAM, Israel -- IM Cannabis Corp., an international medical cannabis company, announced its financial results for the first quarter ended March 31, 2024. All amounts are reported in Canadian dollars and compared to the quarter ended March 31, 2023, unless otherwise stated. Q1 2024 Financial Highlights 13% Revenue increase vs. Q4 2023 of $12.1M vs. $10.7M and 4% decrease vs....